Search results “Triple negative breast cancer research”
Risk factors for developing triple-negative breast cancer
Breast cancer is the most common cancer in women. Among the 1.67 million women diagnosed each year, 15% are diagnosed with triple-negative breast cancer (TNBC). More common in women under the age of 50, TNBC has limited treatment options and is associated with particularly poor survival rates. Knowing the signs and symptoms of breast cancer is essential for early diagnosis and treatment. For more information on TNBC, visit https://www.roche.com/dam/jcr:83655b8... Subscribe to our YouTube channel now: https://www.youtube.com/user/roche?sub_confirmation=1 Get in touch with us: https://www.roche.com/ https://www.facebook.com/RocheCareers https://www.linkedin.com/company/roche https://twitter.com/roche Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: https://www.roche.com/
Views: 6723 Roche
What is triple-negative breast cancer? | Dana-Farber Cancer Institute
Researchers are actively looking for new treatments for triple-negative breast cancer, says Eric Winer, MD, chief of the Division of Women's Cancers at Dana-Farber's Susan F. Smith Center for Women's Cancers. For more information about breast cancer and how it is diagnosed, visit http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Breast-Cancer.aspx?phase=Before_Treatment
Triple Negative Breast Cancer Treatment
Dr. Lisa Newman, director of the Breast Cancer Program at Henry Ford Health System, discusses Triple Negative Breast Cancer among African American women with host, Dr. Lonnie Joe on Primary Care.
Views: 3606 HenryFordTV
Cancer Survivor Story - Denille - Stage 4 Triple Negative Breast Cancer
If you want to learn how Denille beat breast cancer, watch this video now. Her doctors gave her a death sentence… so how is she 100% cancer free today? She was a healthy young woman with two children… until she found a lump in her breast. See how Denille struggled as things went from bad to worse - stage 2 to a devastating stage 4 diagnosis. Why she gave up on conventional treatments. And the amazing story of her message from God about what to do. Next you’ll discover which holistic health doctor for breast cancer healed Denille’s cancer. Her remarkable results in only 2 weeks of all natural breast cancer treatment! And she tells the stories of healing miracles she witnessed in other patients with cancer. Find out about alternative breast cancer treatments that worked for Denille and others. They may work for you and your loved ones who are currently fighting cancer, too. If you like this video, please give it a thumbs up and share it with others you love and care about. WATCH MORE INCREDIBLE CANCER SURVIVOR STORIES: http://bit.ly/cancer-survivor-story-yt ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Have you survived a cancer diagnosis and lived to tell about it? We hear so many amazing stories from our readers about how they beat cancer using the very techniques they’ve learned from The Truth About Cancer… and we’d love to hear YOUR story! Sharing these stories brings hope to those who have been diagnosed with or are currently dealing with cancer. So, if you have a personal story to share of your triumph over cancer, please follow this link and tell us all about it: http://bit.ly/your-cancer-survivor-story-yt . Each week we’ll post a new story on our site from the submissions. ----------------------------------------------------------------------------------------------------------- Visit our website: http://bit.ly/official-website-ttac-yt Join TTAC's 1 million FB fans: http://bit.ly/TTAC-Facebook-YT Follow us on PINTEREST: http://bit.ly/TTAC-Pinterest-YT Find us on INSTAGRAM: http://bit.ly/TTAC-Instagram-YT Support our mission by commenting and sharing with your friends and family below. -------------------------------------------------- About The Truth About Cancer -------------------------------------------------- The Truth About Cancer’s mission is to inform, educate, and eradicate the pandemic of cancer in our modern world. Every single day, tens of thousands of people just like you are curing cancer (and/or preventing it) from destroying their bodies. It’s time to take matters into your own hands and educate yourself on real cancer prevention and treatments. It could save your life or the life of someone you love. --------------------------------------- About Ty Bollinger --------------------------------------- Ty Bollinger is a devoted husband, father, a best-selling author, and a Christian. He is also a licensed CPA, health freedom advocate, cancer researcher, former competitive bodybuilder, and author of the best-selling book Cancer - Step Outside the Box, which has sold over 100,000 copies worldwide. After losing his mother and father and several family members to cancer, Ty’s heartbreak and grief coupled with his firm belief that chemotherapy, radiation, and surgery were the NOT the most effective treatments available for cancer patients led him on a path of discovery. He began a quest to learn everything he possibly could about alternative cancer treatments and the medical industry. What he uncovered was shocking. On his journey, he’s interviewed cutting-edge scientists, leading alternative doctors, and groundbreaking researchers to learn about hidden alternative cancer treatments. What he uncovered help to create The Truth About Cancer and its 3 awe-inspiring docu-series: The Quest for The Cures, The Quest For The Cures Continues, and The Truth About Cancer: A Global Quest. Ty has touched the hearts and changed the lives of thousands of people around the world. Ty speaks frequently at conferences, local health group meetings, churches, and guest stars on multiple radio and TV shows and writes for numerous magazines and websites. ----------------------------------------------------------------------------------------------------------- The Truth About Cancer,truth about cancer,the truth about cancer event,ty bollinger,global quest,a global quest,breast cancer survivor story,cancer survivor stories,how to cure cancer naturally,healing cancer naturally,Alternative cancer treatments,cancer survivor story
Views: 11429 The Truth About Cancer
In Focus: Triple Negative Breast Cancer
As many of you know, I was diagnosed with Triple Negative breast cancer. It was not a happy surprise to learn that some patients with this type of cancer have cells that do not respond to treatment.
Views: 11123 JoanLunden
Triple Negative Breast Cancer - Looking for a triple shot treatment
Triple Negative Breast Cancer - Looking for a triple shot treatment Group 14 - The John Doe's Aidan Bailey David Joubert Boyd Katoka Matthew Nocciolino Gunalini Packiakumar References 1. Chacon RD, Costanzo MV: Triple-negative breast cancer. Breast cancer research. 2010, 12 Suppl 2:S3. Link: http://www.biomedcentral.com/content/pdf/bcr2574.pdf 2. Feigin ME, Xue B, Hammell MC, Muthuswamy SK: G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. P Natl Acad Sci USA 2014, 111:4191-6. Link: http://www.pnas.org/content/111/11/4191.full.pdf
Triple-negative breast cancers, everything you've always wanted to know |  ECP Symposium
Dr. Reis-Filho Surgical Pathologist, Division of Experimental Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center presents hot topics within triple negative breast cancers, highlighting the current thinking and clinical studies leading to a greater understanding of the disease and how this will ultimately impact the potential of targeted therapy for patients in the future. Watch the video and go to dako.com for more information about cancer diagnostics. http://www.dako.com
Triple Negative Breast Cancer Treatment Implications
Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Immunotherapy and Triple Negative Breast Cancer - Mayo Clinic
A promising new study from Mayo Clinic, in conjunction with Caris Life Sciences, points to immunotherapy as a possible treatment option for patients with the difficult-to-treat triple negative breast cancer mutation. The study was presented this week at the 50th annual meeting of the American Society of Clinical Oncology in Chicago. "This study may change our ability to treat triple negative breast cancer patients," says Barbara Pockaj, M.D., lead investigator of the study and Mayo Clinic surgeon. "We may have signs that these patients can be treated with immunotherapy. We don't have a lot of options for these patients and this would really expand our options."
Views: 4252 Mayo Clinic
Triple Negative Breast Cancer Foundation
The Triple Negative Breast Cancer Foundation's mission is to support research into the causes, diagnoses and treatment into triple negative breast cancer and provide programs and services to the triple negative breast cancer community. For more information, visit http://www.tnbcfoundation.org.
Views: 7294 TNBCFoundation
Beating Triple Negative Breast Cancer with Clinical Trial - Lehigh Valley Health Network
When Rochelle Eroh, of Hamburg, PA, was diagnosed with hormone receptor negative and HER2 neu negative (also known as triple negative) breast cancer, she quickly learned this was a more aggressive type of breast cancer. Given her young age and the size of her tumor, Lehigh Valley Health Network medical oncologist, Nicholas Lamparella, DO, provided Rochelle with information regarding a clinical trial for a neo-adjuvant chemotherapy regimen. She received the standard of care Paclitaxel, plus or minus two additional drugs, Carboplatin and Veliparib. In this video, Rochelle, breast cancer surgeon, Lori Alfonse, DO, and Rochelle's clinical trial nurse, Morgan Horton, describe Rochelle's experience and the additional level of care provided as part of the clinical trial. Lehigh Valley Health Network is part of the Memorial Sloan Kettering Cancer Alliance, an initiative to improve the quality of care and outcomes for patients with cancer in community health settings. Innovations at MSK, a world leader in cancer research, brings the latest treatments to community providers - and their patients - at an accelerated pace. For more information, call 610-402-CARE or go to LVHN.org/cancer.
Clinical Trial of a Treatment for Triple Negative Breast Cancer
Surgical oncologist Adam Berger, MD, discusses a clinical trial for patients with triple negative breast cancer. Learn more about breast cancer care at Jefferson: http://sm.tjuh.org/KXk
Views: 325 Jefferson Health
New Triple Negative Breast Cancer Study Launched
Dr. Kristi Funk announces the launch of a new study for Triple Negative breast cancer patients, using Cynvenio's non-invasive liquid biopsy technology to identify and monitor early signs of metastasis.
Views: 23895 Pink Lotus Power Up
Triple Negative Breast Cancer Awareness Day
There are many types of breast cancer. Triple negative breast cancer is one type that is in need of more research.
A triple-negative breast cancer survivor's advice to cancer patients
Bree Sandlin was diagnosed with stage 3 triple-negative breast cancer when she was 37-years-old. After a year of treatment that included chemotherapy, surgery and radiation, there is no trace of cancer. Bree gives her advice to others that have been diagnosed with cancer. http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/breast-cancer/index.html
Dr. Arun on Ongoing Research in Triple-Negative Breast Cancer
Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).
Views: 81 OncLiveTV
Triple negative breast cancer | Dana-Farber Cancer Institute
Nancy Lin, MD, and Geoffrey Shapiro, MD, PhD, explain research and treatment in triple negative breast cancer to attendees at the fifth annual metastatic breast cancer forum for patients and families, held at Dana-Farber on September 24, 2016. Learn more about Dana=Farber’s program for patients with metastatic breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center/Metastatic-Breast-Cancer-Expertise.aspx
Advances In Triple Negative Breast Cancer Treatment
Learn about the most recent research in treating triple-negative breast cancer treatment from medical oncologist David A. Margileth, MD. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Triple-Negative Breast Cancer Survivor Tanya Hall
After her diagnosis with triple-negative breast cancer, Tanya Hall has undergone a series of treatments. She credits cancer research for the advances that led to her successful treatment. That's why she has joined with the American Association for Cancer Research (AACR) to run in the AACR Rock 'n' Roll Philadelphia Half Marathon on Sept. 18, 2016. Learn how you can join Tanya to support lifesaving cancer research at www.RunnersForResearch.org.
Proposed Clinical Trial Could Change Triple Negative Breast Cancer Treatment
Triple-negative breast cancer is a moniker give to a particularly aggressive group of breast cancers that often affect younger women. Because triple-negative breast cancers are not homogenous, and every single patient responds differently to various chemotherapies, it’s difficult to predict which chemotherapy will best treat each patient's cancer. But the researchers at the UK Markey Cancer Center are working to change that paradigm. Markey’s Breast Translational Group is currently developing a proposed clinical trial that could take the guesswork out of prescribing the second round of chemotherapy by treating a set of animal model “avatars” with the different therapies to gauge the response. To donate to help Markey get this clinical trial started, go to ukmarkey.org/donate and select “Tribute Gift.”
Triple-negative Breast Cancer Clinical Trial Calling for Participants
An ongoing research program, led by Edith Mitchell, M.D., FACP, Clinical Professor of Medicine and Clinical Oncology at the Kimmel Cancer Center at Jefferson and Hallgeir Rui, M.D., Ph.D., Professor of Cancer Biology, has initiated a new clinical trial at the Kimmel Cancer Center at Thomas Jefferson University that offers a more customized and personalized approach to the treatment of triple-negative breast cancer. The trial, with lead investigators Drs. Tiffany Avery in the Department of Medical Oncology and Adam Berger in the Department of Surgery, offers treatment in the form of chemotherapy paired with a supplemental medication called a "Parp Inhibitor" and is designed to target the breast cancer cells to increase response to treatment and decrease the risk of recurrence. Researchers will conduct a randomized two-arm trial in 12-week cycles by administering different types of medicines in addition to chemotherapy. Triple-negative breast cancer cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces. This type of breast cancer diagnosis is more prevalent in younger women and in African-American women. Triple-negative breast cancers tend to grow faster and more aggressively and spread to other parts of the body more quicker than most other types of breast cancer. Drs. Mitchell and Rui and their team of researchers are hoping to increase the efficiency and effectiveness of treatment for triple-negative breast cancer through this clinical trial. If you think you may be a potential candidate for this clinical study, please contact the study coordinator, Melisa Mordenti, at 215-955-8979.
Views: 1197 PABreastCancer
Study Findings: Testosterone and Triple Negative Breast Cancer - Mayo Clinic
Could blocking an androgen ( testosterone) receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at the Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix, Ariz are exploring. Preliminary results of a Mayo Clinic -- TGen collaborative study show the androgen receptor may be a potential target to attack in treating triple negative breast cancer (TNBC). Barbara Pockaj, M.D., a surgical oncologist at the Mayo Clinic in Arizona, discusses the study findings and the next steps in research.
Views: 3769 Mayo Clinic
Blueberries: A Triple Threat Against Triple-Negative Breast Cancers
City of Hope cancer center researchers and study authors Shiuan Chen, Ph.D., and Lynn Adams, Ph.D. discuss the results of a research study on the effects of blueberries on breast cancer. Chen, research fellow Lynn S. Adams, Ph.D., and their colleagues applied blueberry extracts to TNBC cell cultures and found that blueberry extract not only inhibits proliferation and mobility in TNBC cells, it also led to cell death (apoptosis) at over twice the rate of untreated cells. Chen, Adams and others then tested blueberry extracts effectiveness in laboratory animal models. The researchers found that the blueberry groups TNBC tumor weight was 70 percent lighter than the control group and it also exhibited significantly lower proliferation and higher apoptosis activity. ################ CONNECT WITH US WEBSITE: http://www.cityofhope.org FACEBOOK: http://www.facebook.com/cityofhope TWITTER: http://www.twitter.com/cityofhope YOUTUBE: http://www.youtube.com/cityofhopeonline FLICKR: http://www.flickr.com/cityofhope BLOG: http://breakthroughs.cityofhope.org and MORE: http://www.cityofhope.org/getsocial ################ ABOUT CITY OF HOPE City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with clinics throughout southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit http://www.cityofhope.org.
Views: 7977 City of Hope
Neelima Denduluri, MD -- Treatment of Triple Negative Breast Cancer
Neelima Denduluri, MD Treatment of Triple Negative Breast Cancer Oncology Outlook 2018 USA MCI
Dr. Finn on Current Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC). For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 72 Targeted Oncology
Triple Negative Breast Cancer & Its First Targeted Therapy Research
Andres Forero, MD, Professor of Medicine, Division of Hematology/Oncology, and Experimental Therapeutics Program Co-Leader at University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, Alabama
Triple-Negative Breast Cancer From Every Angle
Hear the latest about triple-negative breast cancer from our guest panelists, including some of the myths surrounding it and the research being done to find new treatments. The panel will also discuss side effects, the unique emotional concerns for people with TNBC and how to find a support system. About Our Panelists Helen L. Coons, PhD, ABPP is a board certified clinical health psychologist with over 25 years of professional experience with women and men with cancer, oncology health care providers and the cancer advocacy community. She routinely provides care to women across the life span with early and advanced breast, gynecologic and other cancer diagnoses before, during and after treatment, as well as women at “high risk” for cancer, and caregivers. Dr. Coons is a member of LBBC’s Medical Advisory Board and the advisory committee for an advanced breast cancer survey for Novartis' oncology division. Linda Cooper, LCSW, OSW-C is a licensed clinical social worker and a certified oncology social worker. She joined Rocky Mountain Cancer Centers in the spring of 2008. Linda has worked as a social worker in oncology and psychiatry services, hospitals and clinics, hospice programs, hospital emergency rooms, and geriatric settings. She is especially committed to working with older adults on their cancer journey and advocating for all cancer patients as they cope with quality of life issues. Moderator Janine E. Guglielmino, MA Senior Director, Programs and Partnerships Living Beyond Breast Cancer
Dana-Farber Facebook Live Webchat: Triple Negative Breast Cancer
On Aug. 1, 2017, Ann Partridge, MD, MPH, Director of the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute, discussed address advancements in research and treatment for women with triple negative breast cancer on Facebook Live. For more information on how breast cancer is treated at Dana-Farber, visit dana-farber.org/breastcancer.
Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer
Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).
Views: 162 OncLiveTV
DR. KIMBERLY KOSS - Koss National Triple Negative Breast Cancer Research Foundation
2016 Cincinnati Rotary Jefferson Award Finalist
Treatment of Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC). Most trials reported today are in metastatic TNBC, but areas that need more attention are HER2+ disease and hormone-refractory hormone-receptor positive breast cancer, said Nanda. Knowledge of the role of immune checkpoint inhibition within these subtypes of breast cancer is needed as well. Nanda is also hoping combination therapy with immune checkpoint inhibitors, vaccines, and other therapies will help to improve the current response rates.
Views: 1200 Targeted Oncology
Stories of Hope: Terry Arnold, Triple-Negative Breast Cancer Patient
After a desperate, four-month search for a diagnosis, Terry Arnold received the news. Her doctor had discovered, not one, but two of the most deadly and aggressive forms of breast cancer. She had triple-negative breast cancer in both breasts and inflammatory breast cancer in her right breast. With his eyes full of tears, Arnold's doctor told her to get her affairs in order. She had a few months at best. Triple negative breast cancer (TNBC) differs from more common forms of breast cancer in that its cells lack estrogen and progesterone receptors. As a result, it spreads more quickly and doesn't respond to standard hormone therapy treatments. TNBC accounts for 10 to 20% of breast cancer cases in the U.S. and accounts for one of every four breast cancer-related deaths. While TNBC disproportionately strikes younger women, Arnold, a mother of five and grandmother of five, was 49 when she decided to get a second opinion at MD Anderson. "My doctor reran the tests and said, 'It's actually worse than your first doctor thought, but we think we can help you.' To have someone say that, was incredible," Arnold recalls. "I was very excited because he said, 'You'll be in treatment for 18 months, and it will be brutal.' I remember thinking that means he thinks I'm going to live 18 months. I was the happiest woman in the world because they had a plan. I just floated home." It's been six years since Arnold's diagnosis, and she's living cancer-free. She's used this time to form The IBC Network Foundation, which has donated more than $100,000 to breast cancer research at MD Anderson, and mentors hundreds of women fighting this disease. Arnold frequently picks up patients from the airport and meets them for their appointments, making sure they ask all the right questions. She also says she's been to more funerals than anyone should have to attend. "I've literally been with women from their first appointment to the day they rang that bell (to celebrate the end of treatment) and every step in between. To see them live when they were so ill, you just can't put a price tag on that," Arnold says. "I've also been with women minutes before they've died, and the privilege of being in a place that's so deep in their lives is something that very much drives me. Both the joys and the memories I share with these women provide encouragement and push me forward." A devout MD Anderson supporter, Arnold listened from the audience as the Moon Shots Program launched in 2012. She was overjoyed to hear that MD Anderson had selected her cancer, TNBC, as one of the six initial moon shots. "What this means to me is that women are going to live longer to raise their babies and have the impact on society they were meant to have. Without this research, none of that would be possible," Arnold says. "This disease is so brutal and progresses so quickly. We desperately need more research on TNBC. I'm alive and well after six years. That's not common. I think it can be, however, and I think MD Anderson is the place to make it happen." MD Anderson's Breast and Ovarian Cancers Moon Shot aims to combine the latest treatment technology and genetic knowledge to identify the most promising new treatments and move them to a clinical setting in a faster, more efficient way. It's a mission Arnold celebrates. "Private funding for research is more important than ever," she says. "And if MD Anderson is giving its time and resources to champion such a brutal disease, we need to support these efforts all the way." For more information and to make a donation, visit: cancermoonshots.org
Views: 4407 myGivingToMDAnderson
Triple Negative Breast Cancer Research
Triple Negative Breast Cancer Research
Views: 31 CBS 42
SMU Research: Women with Triple Negative breast cancer
Groundbreaking research looks at women fighting Triple Negative Breast Cancer — an aggressive subtype striking 10 to 20 percent of women with breast cancer — typically young, African-American/Hispanic, or testing positive for BRCA1 gene mutation, says psychologist Georita Frierson of Southern Methodist University.
Views: 728 SMUVideo
Researchers Identify New Target For Triple Negative Breast Cancer
Elizabeth Mittendorf, M.D., Ph.D., discusses new research that could help stimulate the body's immune system to destroy cancer cells.
Triple Negative Breast Cancer Update
Eric P. Winer, MD, Dana-Farber Cancer Institute (Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research) discusses triple negative breast cancer.
What's New & Developing in Triple Negative Breast Cancer Research?
On this episode of the Weekly Wellness Channel, Dr. Aaron Williams hosts Dr. Rodney Nash, Co-Founder, President and CEO of Jeevan Biosciences. They discuss the research and developments that are taking place at this Atlanta based biotech firm concerning Triple Negative Breast Cancer.
USciences 16th Annual Research Day: Anti-triple Negative Breast Cancer Compound
Jaspal Brar BI’18 presented research he has been doing in the lab of Bela Peethambaran PhD, focused on the use of Myrothamnus flabellifolius, a South African medicinal plant which contains extracts that are selectively toxic to breast cancer cells, while leaving healthy cells unaffected. Brar’s research showed that the compound made from the plant is effective to kill cancer cells but left the non-cancerous cells unharmed.
Views: 68 USciences
Dr Fiona Simpson - Triple Negative Breast Cancer Research Discovery
Dr Fiona Simpson's research discovery fighting triple negative breast cancer, one of the more difficult breast cancer's to treat. This research is proudly funded by the PA Research Foundation. Find out more about Project Pink at www.projectpink.org.au. Donate to life-saving cancer research and help make pink just a pretty colour again.
Genomically Directed Therapy for Triple Negative Breast Cancer
Do you have triple negative breast cancer? Did you have pre-operative chemotherapy with residual disease after surgery? You might be eligible for a clinical trial using an FDA-approved drug that is selected based on genetic differences in your tumor, versus the standard approach. Learn more: http://hoosiercancer.org/clinical-trials/trial/bre12-158/
Biothera Melanoma/Triple Negative Breast Cancer Phase 2 Study Protocol
Richard Huhn, MD, SVP and Medical Director of Biothera Pharmaceuticals, briefly describes the study protocol for the Company's phase 2 clinical trial in melanoma/triple negative breast cancer. The study is evaluating the therapeutic combination of Biothera's Imprime PGG, a developmental cancer immunotherapy, and Merck's Keytruda.
AR+ Triple Negative Breast Cancer Clinical Trial
Learn about a phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer. http://www.bigtencrc.org
How a triple-negative breast cancer survivor became cancer-free
Bree Sandlin was diagnosed with stage 3 triple-negative breast cancer when she was 37-years-old. After a year of treatment that included chemotherapy, surgery and radiation, there is no trace of cancer. Bree talks about her journey. http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/breast-cancer/treatment/index.html
Triple-negative breast cancer
V. Dieras reports that there are no changes in practice after presentation of studies in triple-negative breast cancer at ASCO 2015. She elaborates the results of adjuvant phase III TITAN study that investigated a role of ixabepilone, and phase III BEACON study with etirinotecan pegol in advance setting. After that she explores the biology of disease, in particular AR and PD-L1 expression, as well as BRCA1 status that open a possibility for studying new agents. http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
TNT Study in Triple Negative Breast Cancer
In this segment, Debu Tripathy, MD; Joyce O’Shaughnessy, MD, and Edith Perez, MD, examine results from the TNT clinical trial, which evaluated the use of docetaxel or carboplatin in individuals with triple negative breast cancer.
Views: 678 OncLiveTV
Triple Negative Breast Cancer Researcher: Dr. Lisa A. Newman
Lisa A. Newman, MD, MPH, FACS, Director, Breast Care Center, Professor of Surgery at University of Michigan Comprehensive Cancer Center, discusses triple negative breast cancer research.
Views: 2018 TNBCFoundation
What Are The Chances My Cancer Will Return After A Triple Negative Diagnosis? - Dr. Margileth
Dr. Margileth defines a triple negative breast cancer as breast cancers that have negative estrogen receptor, negative progesterone receptor and negative HER2/neu gene. He further describes treatment options and risk of recurrence. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. *** This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Metastatic TNBC & IBC - Dr. Lisa Carey - 2014 MBCN Conference at UNC
Comprehensive review of current diagnosis, treatment and monitoring of Triple Negative Breast Cancer and Inflammatory Breast Cancer in the metastatic setting.
Dr. Denise Yardley on the Challenges in Treating Triple Negative Breast Cancer
Denise Yardley, MD, a medical oncologist at the Sarah Cannon Cancer Research Institute in Nashville, Tennessee, discusses the challenges of treating triple negative breast cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 132 Targeted Oncology
Triple Negative Breast Cancer AND Dandruff
Triple Negative Breast Cancer is a more aggressive form of breast cancer which occurs more frequently in African American women, and almost all risk factors can be modified with diet and lifestyle change. Dandruff is not contagious or life-threatening, but sometimes embarrassing and hard to get rid of. Here’s what causes it, and how to prevent and get rid of it.
Views: 1587 Pamela Popper